There is an extensive body of scientific literature on omega-3 fatty acids and joint health. This page gives a neutral overview of what individual studies and meta-analyses report on omega-3 and joints — with specific study details, the doses investigated and the methodological limitations. Important to note first: for omega-3 and joints, rheumatism, arthritis, inflammation or pain there is no EFSA-authorised health claim. All observations described below are to be understood solely as the results of individual studies and constitute neither a promise of effect nor a recommendation for treatment. In the case of joint complaints, medical assessment is essential.
Studies look at the omega-6:3 ratio. Your own level is shown by a fatty acid analysis from your blood.
Test & prices →Background: why omega-3 is investigated in connection with joints
Rheumatoid arthritis (RA) is an autoimmune disease in which the immune system attacks the body's own structures in the joints — primarily the joint lining (synovium). The medical literature describes cytokines such as TNF-alpha, IL-1 and IL-6 as playing a role in this. These relationships are the subject of basic research and form the background against which omega-3 has been scientifically investigated.
The mechanisms described in studies
Studies describe that omega-3 fatty acids are associated with inflammatory markers such as TNF-alpha and IL-6 (see on this the page Omega-3 and inflammation). In cell culture and animal models, an influence on the arachidonic acid cascade, from which certain signalling substances arise, has also been described. These mechanisms are documented in experimental models; their transferability to humans is the subject of research and not conclusively clarified.
Important terms
Morning stiffness is a cardinal symptom of RA: after waking, affected joints are stiff and painful for at least 30–60 minutes. The duration of morning stiffness is a clinical marker of inflammatory activity. NSAID consumption (non-steroidal anti-inflammatory drugs such as ibuprofen, naproxen, diclofenac) is a frequent secondary endpoint in RA studies: if patients need fewer analgesics, this indicates better symptom control.
RA vs. osteoarthritis: an important distinction
Rheumatoid arthritis (RA) is an autoimmune condition with chronic joint inflammation — typically affecting the small joints of both hands symmetrically. Osteoarthritis, by contrast, is a degenerative disease caused by cartilage wear affecting primarily large, weight-bearing joints. More studies on omega-3 are available in the context of RA than for osteoarthritis. The approaches discussed in research also differ: in RA, inflammation-related mechanisms are the focus of investigations; in osteoarthritis, questions of cartilage metabolism are more prominent.
The evidence: what do the meta-analyses report?
Omega-3 and joint complaints are among the comparatively frequently investigated topics in omega-3 research. The following three meta-analyses and systematic reviews are regularly cited in the specialist literature. Their results are reproduced here solely as study observations — they do not prove an effect in the individual case and do not establish a health-related benefit:
Lee YH et al.: meta-analysis of 10 RCTs
This meta-analysis by Lee YH, Bae SC and Song GG evaluated 10 randomised controlled trials. The authors reported that at the doses investigated (study protocols from about 2.7 g EPA+DHA per day over at least 3 months), statistically significant differences in reported joint complaints, morning stiffness and documented analgesic use were observed in the evaluated data (for the endpoint of joint pain the authors gave SMD −0.518; 95% CI −0.915 to −0.121; P = 0.011). This describes the result of the analysis and does not constitute a promise of effect.
Abdulrazaq et al.: systematic review of 18 RCTs, 1,143 participants
This systematic review by Abdulrazaq M, Innes JK and Calder PC evaluated 18 randomised trials with a total of 1,143 participants. In 10 of the 18 studies, the respective authors reported statistically significant differences in reported joint complaints compared with the control group; in the remaining studies this was not the case. The review authors described in the evaluated data an association with the dose investigated (study protocols of 3–6 g EPA+DHA per day). This is an evaluation of published studies, not a treatment recommendation.
Frontiers in Medicine (2025): meta-analysis on chronic pain
This meta-analysis addressed omega-3 and chronic pain and included participants with arthritis among others. The authors gave an overall result of SMD = −0.55 (95% CI −0.76 to −0.34). In the time-course analysis they reported increasing effect sizes with longer intake duration (after 1 month SMD = −0.27; after 3 months SMD = −0.55; after 6 months SMD = −0.83). These figures describe the statistical evaluation of the included studies and do not permit any individual statement of effect.
What endpoints were measured in the RA studies?
The studies on omega-3 in rheumatoid arthritis used a broad spectrum of clinical endpoints:
| Endpoint | Measurement method | Result in meta-analyses |
|---|---|---|
| Joint pain | VAS (visual analogue scale 0–100), NRS | Significant difference reported (≥2.7 g/day) |
| Morning stiffness (duration) | Minutes after waking | Significant difference reported |
| Number of tender joints | Joint count (28-joint score) | Difference reported in several studies |
| Number of swollen joints | Swollen joint count | Inconsistent results reported |
| NSAID consumption | Dose in mg/day or frequency | Significant difference reported (Lee 2012) |
| DAS28 | Disease Activity Score (28 joints) | Difference reported in individual studies |
| Inflammatory markers (CRP, ESR) | Laboratory values | CRP difference reported in umbrella meta-analysis |
The endpoint of analgesic use in the studies
Some of the studies recorded the documented use of analgesics (NSAIDs) as a secondary endpoint. Such endpoints are collected because NSAIDs can be associated with risks in long-term use: gastrointestinal bleeding and ulcers, cardiovascular risks (especially with COX-2 inhibitors) and renal strain in pre-existing kidney impairment.
The meta-analysis by Lee et al. (2012) reported a statistically significant difference in the evaluated data for this endpoint. This figure describes a study observation; it is not evidence that omega-3 changes the need for medication in the individual case, and not a prompt to adjust existing medication.
Omega-3 is not a medicine
Omega-3 supplements are food supplements and not a substitute for analgesics or other medically prescribed medications. Any change or reduction of medication may only take place in consultation with the treating doctor — never independently on the basis of study observations.
Quality of studies and limitations
The meta-analyses are methodologically solid, but have some limitations important for a realistic assessment:
Study heterogeneity
Included studies differ considerably in dosage (0.9–6 g EPA+DHA/day), study duration (3–12 months), number of participants (a few dozen to several hundred), EPA-to-DHA ratio and supplement used (fish oil, borage oil, concentrated EPA). This heterogeneity makes precise dosage recommendations difficult.
Blinding and placebo
Many older fish oil studies had blinding problems: the typical fishy smell and taste can reveal treatment group allocation. More recent studies use odourless capsule formulations and better-matched placebos (e.g. olive oil).
Background medication
Most RA patients in studies were already taking DMARDs (such as methotrexate). Omega-3 was therefore investigated as an add-on to standard treatment. Extrapolation to untreated patients or other forms of arthritis is limited.
Spondyloarthritis, psoriatic arthritis and other forms of arthritis
Most studies relate to rheumatoid arthritis. For other inflammatory forms of arthritis such as psoriatic arthritis, ankylosing spondylitis or reactive arthritis, the data are considerably more limited. A few small studies describe similar mechanisms — but robust meta-analyses are lacking, so no statements can be derived on this.
In osteoarthritis (gonarthrosis, coxarthrosis), the evidence is inconsistent. Some studies report observed differences, others find none — and the approaches discussed in research also differ from those in RA. The Frontiers in Medicine (2025) meta-analysis on chronic pain also included participants with osteoarthritis; its results are to be understood as study observations.
Dosage: what amounts were investigated in the studies?
The following overview summarises which doses were used in the studies and what the respective authors reported on them. The figures describe only study protocols and observed evaluation results — they are not an intake recommendation and not a promise of benefit:
| EPA+DHA dose/day | Observation | Study basis |
|---|---|---|
| < 1.5 g/day | Little or no difference from control groups reported in the analyses | Several RCTs |
| 1.5–2.7 g/day | Inconsistent results reported | Several RCTs |
| ≥ 2.7 g/day (min. 3 months) | Statistically significant differences reported in the analysis | Lee et al. 2012 (meta-analysis) |
| 3–6 g/day | Greatest effect size reported in the review analysis | Abdulrazaq et al. 2017 |
| Intake duration ≥ 6 months | Increasing effect size reported (SMD −0.83) | Frontiers in Medicine 2025 |
Detailed information on dosage recommendations can be found on the page Omega-3 daily dosage: what is reasonable?.
Omega-3 alongside prescribed medications
For people on biologic therapy (TNF blockers such as adalimumab, etanercept or IL-6 inhibitors such as tocilizumab), few large interaction studies exist. The approaches described for omega-3 in research differ from those of the biologics. Robust statements on concurrent use cannot, however, be derived from this. Anyone wishing to take omega-3 supplements in addition to prescribed medications such as methotrexate or other immunomodulators should clarify this with a doctor beforehand.
What do scientific societies say?
The European League Against Rheumatism (EULAR) has incorporated dietary aspects into its recommendations for RA treatment. Consumption of fish and omega-3-rich foods is described as a reasonable complementary measure. Several national rheumatology societies recommend the Mediterranean diet — naturally rich in omega-3 from fish and olive oil — as part of overall management.
Mediterranean diet
The Mediterranean diet is frequently discussed in nutrition research; fish as a natural omega-3 source is a component of it. However, the isolated contribution of individual nutrients can hardly be delineated in observational studies of overall diet. Statements about a concrete effect on joint complaints cannot be derived from such observational data.
Practical assessment
In summary, there is an extensive but inconsistent body of evidence on omega-3 and joints. Some of the studies report observed differences, others do not. For omega-3 and joints, rheumatism or arthritis there is no EFSA-authorised health claim, and omega-3 supplements are not a substitute for medical treatment. Anyone wishing to consider adequate omega-3 supply in older age in general can find information in the article Omega-3 for older adults.
Several studies also describe that observed changes only appeared over several weeks to months. These figures too are study observations and do not allow any conclusion about an individual benefit.
Background on the mechanisms described in research is provided by the page Omega-3 and inflammation. The role of omega-3 in connection with the immune system is covered on the page Omega-3 and the immune system.
Frequently asked questions
Can omega-3 replace medical treatment?
No. Omega-3 supplements are food supplements and not a substitute for medically prescribed treatment or medication. There is no EFSA-authorised health claim for omega-3 and joints. Anyone with a diagnosed condition or taking medication should discuss any change exclusively with their treating doctor.
Which omega-3 doses were investigated in studies on joint health?
The scientific literature has investigated a wide range of doses, frequently in the region of about 2 to 6 g EPA+DHA per day over several months. These figures describe only the amounts used in individual studies and do not constitute an intake recommendation. General information on reference amounts can be found on the page Omega-3 daily dosage.
Over what intake duration do studies on omega-3 report?
Some published studies describe that observed changes only appeared over several weeks to months. The Frontiers in Medicine (2025) meta-analysis, for example, reported effect sizes that increased with longer intake duration. These figures describe study observations and do not permit any individual statement of effect.
What do studies report on omega-3 and osteoarthritis?
The evidence on osteoarthritis (gonarthrosis, coxarthrosis) is inconsistent. Some studies report observed changes, others find no clear difference from the control group. Because osteoarthritis has a different pathophysiology to inflammatory joint conditions, the mechanisms investigated differ. Robust, consistent conclusions are not available.
Are there differences between fish oil and krill oil?
Krill oil contains EPA and DHA predominantly in phospholipid form, fish oil mostly in triglyceride or ethyl ester form. Study results on bioavailability vary. Direct comparative studies in the context of joint health are rare, so no clear statements can be derived on this.
Interaction with anticoagulants and methotrexate
Omega-3 fatty acids have a mild antiplatelet effect. For RA patients taking methotrexate, leflunomide, corticosteroids or anticoagulants, omega-3 intake at higher doses (more than 3 g/day) should be coordinated with the rheumatologist. Intake of low to moderate doses (1–3 g/day) is considered safe and shows no relevant interactions with standard RA medications in clinical studies.
Your next step
How well supplied are you?
Questionnaires estimate, a blood test measures. Start with the free self-check and then decide whether a measurement is worth it for you.
Medical disclaimer
For omega-3 and joints, rheumatism, arthritis, inflammation or pain there is no EFSA-authorised health claim. All study results mentioned on this page are reproduced solely as observations of individual investigations and constitute no promise of effect, no healing claim and no treatment recommendation. This article is for general information purposes and does not replace medical advice. Omega-3 supplements are food supplements and not a substitute for a balanced diet or medical treatment. Joint complaints belong in specialist medical assessment; do not change your medication without consulting your doctor.